The US FDA (Food and Drug Administration) has asked Eli Lilly & Co, Pfizer, and AbbVie, to inform consumers about potential risks relating to their high-profile Janus kinase (JAK) inhibitor medications. The FDA has ordered label warnings that list a heightened risk of severe heart-related issues, cancer, blood clots and death for the approved drugs that include JAK inhibitors to treat certain chronic inflammatory diseases sold in the US. The FDA has similarly asked for updated labels that warm consumers for two other arthritis drugs in the same class as Xeljanz, Rinvoq and Lilly’s drug Olumiant (baricitinib).
Read more here.
More on: News Regulatory